RegenMedEuro

James Lamb has had an extensive career in business, public relations, politics, and academia. After selling a family business and completing his MBA, James began working in academia in workforce training. Later he was involved in a public relations firm and a startup private investigations firm. Upon finishing his second master’s degree, James began teaching graduate level marketing and undergraduate management. He has been active in local and state political circles and much of his business work has involved government relations. His bachelor’s degree was in International Relations. For the past ten years

James has been consulting with startups.

RME owns the rights to sell the drugs developed by

Zhittya Genesis Medicine in Europe.

Contact James Lamb: jameswlamb@att.net

We are advancing a group of drugs which trigger the
human body's natural regeneration process

FGF-1 is a natural protein contained within our

bodies. It is released upon tissue injury and is

the body’s natural response to tissue repair.

FGF-1 stands out due to its potency and its
ability to stimulate the production of not only

capillaries but larger arterioles, which are critical

in bringing more blood into the injured tissue.
Also, FGF-1 is the only growth factor known to

be potently mitogenic for dermal fibroblasts,

vascular endothelial cells, and epidermal
keratinocytes, the three major cell types

present in the skin. These structural properties and biologic activities make it an extremely attractive therapeutic agent to promote dermal healing.

The principals of Zhittya Genesis Medicine have been working with FGF-1 for over 25 years. Their experience includes the manufacturing and quality control of FGF-1 and the design and successful implementation of FDA-approved clinical trials for the healing of diabetic foot ulcers and coronary artery disease.

Regenerative Medicine of Europe (RME) believes that Regenerative Medicine is the future of healthcare. RME believes that many of the problems of our aging bodies are from the lack of blood flow to organs which can cause a cascade of negative effects on the body and our health.

According to the European Heart Network, each year cardiovascular disease (CVD) causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union (EU). CVD accounts for 45% of all deaths in Europe and 37% of all deaths in the EU. In 2015, more than 85 million people in Europe were living with CVD and almost 49 million people were living with CVD in the EU. In 2015, there were just under 11.3 million new cases of CVD in Europe and 6.1 million new cases of CVD in the EU.

According to the World Health Organization, there are about 60 million people with diabetes in the European Region. A significant percentage of these patients progress to develop vascular complications of their diabetes including foot ulcers, peripheral vascular disease, and critical limb ischemia.

If we can grow blood vessels to repair damaged hearts, legs and brains and other organs, we can save

lives and improve the quality of those lives. RME owns the exclusive rights to a new regenerative pharmaceutical for Europe that can stimulate blood vessels, nerves and skin growth. The active

molecule in this biologic pharmaceutical is Fibroblast Growth Factor 1 (FGF-1). It is being developed by Zhittya Genesis Medicine (ZGM).

ABOUT US

Contact John Laub: John@regenmedeuro.com

1120 N. Town Center Drive Suite 270, Las Vegas, NV 89144 USA
PH: 702.800.0030
Toll Free: 1.844.999.0030

John Laub is the President and CEO of Regenerative Medicine of Europe, Inc. John ran the Regenerative Medicine Organization for over 10 years. He also founded and is the President of the Nevada Biotechnology & Health Science Consortium. He is the Chairman of the Board of Advisors for the University of Nevada, Las Vegas College of Sciences.

JAMES LAMB, Vice President of Marketing

JOHN LAUB, CEO